Tag: R-Pharm

R-Pharm is a Russian private hi-tech pharmaceutical company founded in 2001, employs over 3500 highly qualified specialists, has over 60 branches. Turnover reached over $ 1,5 billion in 2013. R-Pharm operates in Russia and CIS, USA, Germany, Japan and India. The company is involved in R&D, manufacturing, marketing, sales and distribution of innovative pharmaceutical products from a broad number of therapeutic areas in specialty/hospital care. The company has operational GMP compliant manufacturing sites at Yaroslavl, Kostroma region and Germany and Novosibirsk/ R-Pharm is building a modern facility for the synthesis of active pharmaceutical ingredients in Rostov – Pharmoslavl. It is expected that the first phase of Pharmoslavl site will be put into operation in the end of 2016. The new facility will comply with the highest requirements of environmental and occupational safety and health standards for the workplace.

Over the time of operation of its manufacturing facilities the company has successfully passed audits and evaluation visits from the largest Global Pharma companies, such as Abbvie, Amgen, Astellas, AstraZeneca, BMS, Boryung, Dr.Reddy’s, Eli Lilly, Ferring, Glaxo Smith Kline, Johnson& Johnson, Mallinckrodt, MSD, Pfizer, Roche, and Sanofi. The R-Pharm’s facilities in the Yaroslavl and Kostroma regions implement dozens of complex advanced production technologies, which haven’t been used previously in the Russian Federation.

R-Pharm has invested in the establishment of biopharmaceutical products manufacturing facility based on FlexFactory processing line from the U.S. company Xcellerex. This facility is the first step towards the mass production of biologic drugs including innovative products and biosimilars. The plant will simultaneously be certified in the USA to meet the FDA and GMP requirements and will be the first of its kind production in Russia. Through this project the company will be able to deliver innovative medicines for the treatment of many socially significant diseases. As part of the investment agreement, Xcellerex will provide training to R-Pharm specialists in order to ensure the most rapid and effective transfer of technology and knowledge in accordance with GMP production standards and the requirements of international regulatory bodies.

R-Pharm specializes in the supply of high-tech medicinal products and laboratory equipment for the leading federal medical research centers, hospitals and clinical hospitals, as well as the largest regional curative and preventive care institutions of the Russian Federation.

The company’s portfolio includes medicinal products of various pharmaceutical groups, including oncology, hematology, cardiology, immunology, antibacterial, anti-viral, including the treatment of HIV-infection, medicinal products used in organ transplantation, treatment of disseminated sclerosis, hemophilia and diabetes, as well as neuromuscular relaxants, radiopaque contrast agents and drugs for anesthesia.

The company’s core businesses are manufacturing of finished dosage forms, active pharmaceutical ingredients of chemical nature and biotech substances; research and development of innovative products and technologies; bringing the highly efficient pharmaceutical products to the Russian market; as well as implementation of education and training programs for pharmaceutical and healthcare industries.

R-Pharm reported positive results from Phase III clinical trial of remimazolam

clinical trials
R-Pharm Group and the Specialty Pharma Company PAION AG (Germany) announced that the Phase III trial in general anesthesia conducted in Russia has been successfully completed.

Russian-Azerbaijani pharma company to be launched at the end of 2018

hayat
The Azerbaijani-Russian joint venture will be commissioned in December 2018. In December, the drug packaging line will be put into operation, which is the first stage of the project.

Twelve production lines will be constructed in Moscow

pharma-control
The second offset contract for the supply of medicines will be concluded with LLC R-Opra, providing for the reciprocal investment obligations of the supplier-investor.

AbbVie and R-Pharm will launch the full-cycle manufacturing of Kaletra in Russia

R-Pharm
AbbVie, a global research biopharmaceutical company, and R-Pharm Group announced the completion of technology transfer for manufacturing Kaletra intended for treatment of HIV/AIDS infection in adult patients.

R-Pharm is recognized as a leader of anti-corruption reporting practices in Russia

pharma manufacturing
R-Pharm has become a leading Russian company in terms of anti-corruption and anti-bribery practices. This follows from the report published by Transparency International for 2017.

Russian-Japanese cooperation results in a project between R-Pharm and Mitsui

R-pharm
As part of the Russian-Japanese cross-year, the preliminary results have been reported for the activities implemented under the plan adopted in May 2016 during the meeting of Russian President with Japanese Prime Minister.

Fujifilm signed a distribution agreement with R-Pharm

fujifilm
FUJIFILM Corporation signed a distribution agreement with a major Russian pharmaceutical company JSC “R-Pharm” for the distribution of Fujifilm's medical devices in Russia.

R-Pharm will supply Viekira Pak to Russian Ministry of Health

r-pharm
The Ministry of Health of the Russian Federation announced the results of the tender for supply of dasabuvir/ombitasvir/paritaprevir/ritonavir, a new drug for hepatitis C. As it was expected, the declared winner was R-Pharm.

R-Pharm Kazakhstan receives a GDP compliance certificate

manufacturing
In February 2018, the division of R-Pharm Group in Kazakhstan received a certificate of compliance with the Good Distribution Practice (GDP) from the Ministry of Health of the Republic of Kazakhstan. ...

R-Pharm and Human Longevity will establish genome analysis centers in Russia

gene
R-Pharm, a Russian group of companies, and Human Longevity, Inc., an American corporation, have signed an agreement on collaboration in the area of human genome research and diagnostics

TaiGen and R-Pharm completed patient enrollment for clinical trials of Taigexyn

clinical trials
TaiGen Biotechnology Company, Ltd. and R-Pharm Group announced the completion of patient enrollment for phase III clinical trials of Taigexyn

R-Pharm localized full-cycle manufacturing of Glatirat

R-Pharm
Yaroslavl Plant of Finished Dosage Forms and Biotechnological Substances completed the project to localize the full-cycle manufacturing of Glatirat

R-Pharm and PrimeBioMed will develop a quantitative immunohistochemical test

research
R-Pharm Group and PrimeBioMed LLC signed an agreement on joint development of a quantitative immunohistochemical test for the use of drugs blocking PD-1/PD-L1

R-Pharm completes the deal to sell a 10% stake to Mitsui

pharma-deal
October 17 marked the closing of a deal on acquisition of a 10% stake in R-Pharm, a Russian pharmaceutical company, by Mitsui & Co., Ltd.

R-Pharm becomes the first Russian company to conduct clinical trials in South Korea

laboratory
A meeting with the doctors and employees of 8 leading South Korean clinical and university centers was held in Seoul.

A fund established by RDIF and JBIC invests in R-Pharm

dmitriev
The first deal of the joint investment fund established by Japan Bank for International Cooperation and Russian Direct Investment Fund will be investment in R-Pharm